agilon health, the physician-centric Medicare Advantage risk-bearing platform that trades under the symbol AGL, arrived at its June quarter in the middle of the most consequential twelve months in its short public life. A year ago the stock was a sub-dollar penny stock nursing an NYSE delisting notice and a full-year 2025 Adjusted EBITDA loss of $296 million. It executed a 1-for-25 reverse stock split in late March 2026, then watched its shares run from roughly $8 to a mid-July peak near $130 - a roughly sixteen-fold move in about three months - before retreating to around $86. Into that storm of speculation the company delivered something it had not produced in years: a profitable quarter, and guidance raised across the board.
The second quarter is genuinely a turn. Revenue rose 7% to $1.49 billion, gross profit of $107 million replaced a year-ago gross loss of $52 million, medical margin swung from negative $53 million to $197 million, and Adjusted EBITDA turned positive at $70 million against a year-ago loss of $83 million. A year and a half of disciplined, profit-first contracting plus more constructive 2026 Medicare rates finally put the core business above water.
But the quarter deserves a second look, because much of the profit is a look-back. Management's own numbers say so plainly. The full-year 2026 Adjusted EBITDA guidance of $75 million to $95 million sits well below the $123 million earned in just the first half - arithmetic that implies a second-half swing to roughly a $28 million to $48 million loss. The raised guidance is the honest tell: H1 was flattered by favorable prior-year claims development and risk-adjustment timing, and the company expects H2 to normalize back toward breakeven. The investment question is not whether agilon is profitable - it is. It is whether a ~$1.45 billion market capitalization, built on a reverse-split rally, fairly prices a turnaround whose own forward guide points back toward losses in the back half.